CONTACT: Amgen, Thousand Oaks Kristen Davis, 805-447-3008 (media) Arvind Sood, 805-447-1060 (investors)SOURCE Amgen
There's not much reason to be bullish on these stocks.
Regeneron has faced a lower stock price and patent wrangling. But the stock could be ready to rise again.
There could be a major windfall for Fortune 500 companies.